Admune Therapeutics LLC, a clinical stage biotechnology company, was founded by a highly experienced team of scientists and business people with a proven track record in producing successful biomedical products. Admune Therapeutics is affiliated with Marine Polymer Technologies, Inc. (MPT), a provider of ground-breaking medical solutions focused in the areas of hemostasis and wound healing.
Admune Therapeutics is engaged in a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute to conduct R&D and commercialize innovative cytokine cancer therapies that will benefit human health. Through this collaboration, our company is moving forward with a Phase I in-human study of Admune’s lead compound, heterodimeric IL-15:IL-15Ra, for cancer immunotherapy. The trial will be conducted through the National Cancer Institute at the National Institutes of Health.
Cancer immunotherapy or immuno-oncology is a rapidly evolving biotech field and Admune is at the forefront of this research. For more than a decade, we have worked on developing innovative cytokine cancer therapies for treating cancer patients. Admune Therapeutics uses proprietary technologies to advance new immunotherapeutics to the clinic.Admune Therapeutics LLC